First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

If approved, etrasimod will mount a direct challenge to Bristol-Myers Squibb's S1P drug Zeposia (ozanimod), which was approved for UC last year and also for a green light to treat multiple ...

The FDA had approved Velsipity (etrasimod) for UC in October 2023. Velsipity’s approval was based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12. These studies ...

but will be watched keenly to see how it stacks up with etrasimod's main rival, Bristol-Myers Squibb's S1P drug Zeposia (ozanimod), which was approved for ulcerative colitis last year and is also ...